VistaGen Therapeutics, Inc.

162 articles with VistaGen Therapeutics, Inc.

• 

  BioSpace's Global Biopharma Roundup: February 21

  2/21/2019

  Lots of interesting biotech news from Asia, Europe and elsewhere was reported this week. From tapeworms to using a breathalyzer test in lung cancer diagnostics, the global biotech industry is exploding with ideas.
• 

  Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression

  1/16/2019

  Developing treatments to help those struggling with depression, a disorder that can lead to suicide, has become a mission for Shawn Singh, CEO of VistaGen, and his colleagues.

• VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression

  11/13/2018

  VistaGen’s oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.

• 

  VistaGen’s AV-101 Snags Fast Track Designation, Other Drugmakers Move Ahead with Non-Opioid Pain ...

  10/6/2018

  Opioids have shown tremendous efficacy in pain management. At the same time, the dangers of the addiction to the medication have become well-known in recent years as an epidemic has swept across the United States.

• VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain

  10/3/2018

  Designation highlights serious unmet need for new treatment options for patients suffering from neuropathic pain

• VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder

  9/13/2018

  Phase 3-ready asset expands VistaGen’s CNS pipeline and complements its neuropsychiatry focus on Major Depressive Disorder (MDD) with AV-101

• 

  Recent Industry Movement Focuses on Depression Treatments

  6/8/2018

  There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing...
• 

  Janssen Closes in on Seeking FDA Approval for Ketamine-Based Depression Treatment

  5/7/2018

  Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.

• VistaGen Receives Notice Of Allowance From U.S. Patent And Trademark Office For U.S. Patent Regarding Methods Of Production For AV-101

  10/2/2017

• VistaGen Grants Exclusive Sublicense Of Cardiac Stem Cell Technologies To BlueRock Therapeutics

  12/14/2016

• Cash to Operate a Growing Concern for Bay Area's VistaGen

  11/15/2016

• VistaGen Therapeutics, Inc. Appoints Mark A. Mcpartland Vice President Of Corporate Development And Investor Relations

  10/4/2016

• VistaGen Therapeutics, Inc. Provides Business Outlook And Sets Corporate Milestones

  9/22/2016

• VistaGen Therapeutics, Inc. Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. As Chief Medical Officer

  6/20/2016

• VistaGen Therapeutics, Inc. Completes $10 Million Public Offering

  5/13/2016

• VistaGen Therapeutics, Inc. Announces Nasdaq Listing And Pricing Of $10.0 Million Public Offering

  5/11/2016

• VistaGen Therapeutics, Inc. Appoints Jerry Gin, Ph.D., MBA To Its Board Of Directors

  3/30/2016

• VistaGen Therapeutics, Inc. Bolsters Clinical And Regulatory Advisory Board With Appointments Of Distinguished Key Opinion Leaders In Depression

  3/22/2016

• VistaGen Therapeutics, Inc. Secures Exclusive Worldwide Commercial Rights To Three Proprietary Stem Cell Technologies From University Health Network

  12/23/2015

• VistaGen Therapeutics, Inc. Announces First Patient Dosed In NIH-Sponsored Phase 2A Study Of Orally Available AV-101 In Major Depressive Disorder

  11/3/2015